Osteoblasts in prostate cancer metastasis to bone

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., & Masaki, T. (1988) · Nature · doi:10.1038/332411a0 · Cited by 10,729

Osteoclast differentiation and activation

Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×

Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*

JONES, J. I., & CLEMMONS, D. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-3 · Cited by 4,710

Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation

Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., & Karsenty, G. (1997) · Cell · doi:10.1016/s0092-8674(00)80257-3 · Cited by 4,246

Targeted Disruption of Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts

Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y.-H., Inada, M., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80258-5 · Cited by 4,244

The Novel Zinc Finger-Containing Transcription Factor Osterix Is Required for Osteoblast Differentiation and Bone Formation

Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J. M., Behringer, R. R., & de Crombrugghe, B. (2002) · Cell · doi:10.1016/s0092-8674(01)00622-5 · Cited by 3,608

Functional interaction of β-catenin with the transcription factor LEF-1

Behrens, J., von Kries, J. P., Kühl, M., Bruhn, L., Wedlich, D., Grosschedl, R., & Birchmeier, W. (1996) · Nature · doi:10.1038/382638a0 · Cited by 2,912

Cbfa1, a Candidate Gene for Cleidocranial Dysplasia Syndrome, Is Essential for Osteoblast Differentiation and Bone Development

Otto, F., Thornell, A. P., Crompton, T., Denzel, A., Gilmour, K. C., Rosewell, I. R., Stamp, G. W. H., Beddington, R. S. P., Mundlos, S., Olsen, B. R., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80259-7 · Cited by 2,814

VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation

Gerber, H.-P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, Z., & Ferrara, N. (1999) · Nature Medicine · doi:10.1038/9467 · Cited by 2,085

Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study

Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996

LNCaP model of human prostatic carcinoma.

Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789

A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma

Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656

Establishment and characterization of a human prostatic carcinoma cell line (PC-3).

Kaighn, M. E., Ks, N., Ohnuki, Y., Lechner, J. F., & Jones, L. W. (1979) · PubMed · Cited by 1,603

High Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5

Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K., & Lifton, R. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013444 · Cited by 1,591

The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma

Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503

Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover

Street, J., Bao, M., deGuzman, L., Bunting, S., Peale, F. V., Ferrara, N., Steinmetz, H., Hoeffel, J., Cleland, J. L., Daugherty, A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152324099 · Cited by 1,404

A Mutation in the LDL Receptor–Related Protein 5 Gene Results in the Autosomal Dominant High–Bone-Mass Trait

Little, R. D., Folz, C., Manning, S. P., Swain, P. M., Zhao, S.-C., Eustace, B., Lappe, M. M., Spitzer, L., Zweier, S., Braunschweiger, K., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/338450 · Cited by 1,282

Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta -catenin and promotes GSK-3beta -dependent phosphorylation of beta -catenin

Ikeda, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.5.1371 · Cited by 1,246

Armadillo Coactivates Transcription Driven by the Product of the Drosophila Segment Polarity Gene dTCF

van de Wetering, M., Cavallo, R., Dooijes, D., van Beest, M., van Es, J., Loureiro, J., Ypma, A., Hursh, D., Jones, T., Bejsovec, A., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)81925-x · Cited by 1,202

Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor

Kato, M., Patel, M. S., Levasseur, R., Lobov, I., Chang, B. H.-J., Glass, D. A., Hartmann, C., Li, L., Hwang, T.-H., Brayton, C. F., et al. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200201089 · Cited by 1,086

Isolation of a human prostate carcinoma cell line (DU 145)

Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., & Paulson, D. F. (1978) · International Journal of Cancer · doi:10.1002/ijc.2910210305 · Cited by 926

Runx2 Is a Common Target of Transforming Growth Factor β1 and Bone Morphogenetic Protein 2, and Cooperation between Runx2 and Smad5 Induces Osteoblast-Specific Gene Expression in the Pluripotent Mesenchymal Precursor Cell Line C2C12

Lee, K.-S., Kim, H.-J., Li, Q.-L., Chi, X.-Z., Ueta, C., Komori, T., Wozney, J. M., Kim, E.-G., Choi, J.-Y., Ryoo, H.-M., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.8783-8792.2000 · Cited by 865

Low-Density Lipoprotein Receptor-Related Protein-5 Binds to Axin and Regulates the Canonical Wnt Signaling Pathway

Mao, J., Wang, J., Liu, B., Pan, W., Farr, G. H., Flynn, C., Yuan, H., Takada, S., Kimelman, D., Li, L., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00224-6 · Cited by 839 · cited 1×

Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.

Thalmann, G. N., Anezinis, P., Chang, S., Zhau, H. E., Kim, E. E., Hopwood, V. L., Pathak, S., von Eschenbach, A. C., & Chung, L. W. K. (1994) · PubMed · Cited by 727

Serine Phosphorylation-regulated Ubiquitination and Degradation of β-Catenin

Orford, K., Crockett, C., Jensen, J. P., Weissman, A. M., & Byers, S. W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.24735 · Cited by 714

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., & Simons, J. W. (1995) · Nature Medicine · doi:10.1038/nm0995-944 · Cited by 622

The insulin-like growth factor I receptor: a key to tumor growth?

Baserga, R. (1995) · PubMed · Cited by 552

Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma

Cohen, P. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1046 · Cited by 497

Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts.

Gleave, M. E., Hsieh, J., Gao, C. A., von Eschenbach, A. C., & Chung, L. W. K. (1991) · PubMed · Cited by 452

The IGF-I receptor in cell growth, transformation and apoptosis

Baserga, R., Hongo, A., Rubini, M., Prisco, M., & Valentinis, B. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00007-3 · Cited by 439

Osteoprotegerin Produced by Osteoblasts Is an Important Regulator in Osteoclast Development and Function

Udagawa, N., Takahashi, N., Yasuda, H., Mizuno, A., Itoh, K., Ueno, Y., Shinki, T., Gillespie, M. T., Martin, T. J., Higashio, K., et al. (2000) · Endocrinology · doi:10.1210/en.141.9.3478 · Cited by 404

Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice

Klein, K. A., Reiter, R. E., Redula, J., Moradi, H., Zhu, X. L., Brothman, A. R., Lamb, D. J., Marcelli, M., Belldegrun, A., Witte, O. N., et al. (1997) · Nature Medicine · doi:10.1038/nm0497-402 · Cited by 399

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

Tu, S.-M., Millikan, R. E., Mengistu, B., Delpassand, E. S., Amato, R. J., Pagliaro, L. C., Daliani, D., Papandreou, C. N., Smith, T. L., Kim, J., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03639-4 · Cited by 396

Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial

Carducci, M. A., Padley, R. J., Breul, J., Vogelzang, N. J., Zonnenberg, B. A., Daliani, D. D., Schulman, C. C., Nabulsi, A. A., Humerickhouse, R. A., Weinberg, M. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.176 · Cited by 371

LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis

Thalmann, G. N., Sikes, R. A., Wu, T. T., Degeorges, A., Chang, S.-M., Ozen, M., Pathak, S., & Chung, L. W. K. (2000) · The Prostate · doi:10.1002/1097-0045(20000701)44:2<91::aid-pros1>3.0.co;2-l · Cited by 366

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

Sartor, O., Reid, R. H., Hoskin, P. J., Quick, D. P., Ell, P. J., Coleman, R. E., Kotler, J. A., Freeman, L. M., & Olivier, P. (2004) · Urology · doi:10.1016/j.urology.2004.01.034 · Cited by 365

A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer

Quilty, P. M., Kirk, D., Bolger, J. J., Dearnaley, D. P., Lewington, V. J., Masone, M. D., Reed, N. S. E., Russell, J. M., & Yardley, J. (1994) · Radiotherapy and Oncology · doi:10.1016/0167-8140(94)90411-1 · Cited by 335

VCaP, a cell-based model system of human prostate cancer.

Korenchuk, S., Lehr, J. E., McLean, L. L., Lee, Y.-G., Whitney, S. C., Vessella, R. L., Lin, D. L., & Pienta, K. J. (2001) · PubMed · Cited by 323

Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.

Craft, N. A., Chhor, C. M., Tran, C., Belldegrun, A. S., deKernion, J. B., Witte, O. N., SAID, J. W., Reiter, R. E., & Sawyers, C. L. (1999) · PubMed · Cited by 292

Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines

Wu, T. T., Sikes, R. A., Cui, Q., Thalmann, G. N., Kao, C., Murphy, C. F., Yang, H., Zhau, H. E., Balian, G., & Chung, L. W. K. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980911)77:6<887::aid-ijc15>3.0.co;2-z · Cited by 291

Spread of prostatic cancer to bone

Jacobs, S. C. (1983) · Urology · doi:10.1016/0090-4295(83)90147-4 · Cited by 286

Vasculotropin/Vascular Endothelial Growth Factor Induces Differentiation in Cultured Osteoblasts

Midy, V., & Plouet, J. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1240 · Cited by 285

Expression of Concern: Up‐regulation of Wnt‐1 and β‐catenin production in patients with advanced metastatic prostate carcinoma

Chen, G., Shukeir, N., Potti, A., Sircar, K., Aprikian, A., Goltzman, D., & Rabbani, S. A. (2004) · Cancer · doi:10.1002/cncr.20518 · Cited by 283

Vascular Endothelial Growth Factor (VEGF) Expression in Human Prostate Cancer: In Situ and in Vitro Expression of VEGF by Human Prostate Cancer Cells

Ferrer, F. A., Miller, L. J., Andrawis, R. I., Kurtzman, S. H., Albertsen, P. C., Laudone, V. P., & Kreutzer, D. L. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64775-x · Cited by 278

Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease

Cohen, P., Peehl, D. M., Graves, H. C. B., & Rosenfeld, R. G. (1994) · Journal of Endocrinology · doi:10.1677/joe.0.1420407 · Cited by 268

Establishment of two human prostate cancer cell lines derived from a single bone metastasis.

Navone, N. M., Olivé, M., Özen, M., Davis, R., Troncoso, P., Tu, S., Johnston, D., Pollack, A. S., Pathak, S., von Eschenbach, A. C., et al. (1997) · PubMed · Cited by 265

The Protein Kinase C Pathway Plays a Central Role in the Fibroblast Growth Factor-stimulated Expression and Transactivation Activity of Runx2

Kim, H.-J., Kim, J.-H., Bae, S.-C., Choi, J.-Y., Kim, H.-J., & Ryoo, H.-M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m203750200 · Cited by 236

Dissociation between bone resorption and bone formation in osteopenic transgenic mice

Corral, D. A., Amling, M., Priemel, M., Loyer, E., Fuchs, S., Ducy, P., Baron, R., & Karsenty, G. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13835 · Cited by 229

Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications

Jung, K., Lein, M., Stephan, C., Von Hösslin, K., Semjonow, A., Sinha, P., Loening, S. A., & Schnorr, D. (2004) · International Journal of Cancer · doi:10.1002/ijc.20314 · Cited by 225

CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.

Wainstein, M. A., He, F., Robinson, D. R., Kung, H., Schwartz, S., Giaconia, J. M., Edgehouse, N. L., Pretlow, T. P., Bodner, D. R., & Kursh, E. D. (1994) · PubMed · Cited by 225

Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.

Nemeth, J. A., Harb, J. F., Barroso, U., He, Z., Grignon, D. J., & Cher, M. L. (1999) · PubMed · Cited by 221

Preoperative Plasma Levels of Transforming Growth Factor Beta1 (TGF-β1) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy

Shariat, S. F., Shalev, M., Menesses-Diaz, A., Kim, I. Y., Kattan, M. W., Wheeler, T. M., & Slawin, K. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2856 · Cited by 214

Prostate Specific Antigen Cleaves Parathyroid Hormone-Related Protein in the PTH-like Domain: Inactivation of PTHrP-Stimulated cAMP Accumulation in Mouse Osteoblasts

Cramer, S. D., Chen, Z., & Peehl, D. M. (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)65919-6 · Cited by 192

Establishment and characterization of osseous prostate cancer models: Intra‐tibial injection of human prostate cancer cells

Corey, E., Quinn, J. E., Bladou, F., Brown, L. G., Roudier, M. P., Brown, J. M., Buhler, K. R., & Vessella, R. L. (2002) · The Prostate · doi:10.1002/pros.10091 · Cited by 192

An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells

Rabbani, S. A., Desjardins, J., Bell, A. W., Banville, D., Mazar, A., Henkin, J., & Goltzman, D. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80893-9 · Cited by 174

LuCaP 35: A new model of prostate cancer progression to androgen independence

Corey, E., Quinn, J. E., Buhler, K. R., Nelson, P. S., Macoska, J. A., True, L. D., & Vessella, R. L. (2003) · The Prostate · doi:10.1002/pros.10198 · Cited by 160

Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.

Ellis, W. J., Vessella, R. L., Buhler, K. R., Bladou, F., True, L. D., Bigler, S. A., Curtis, D., & Lange, P. H. (1996) · PubMed · Cited by 153

Vascular Endothelial Growth Factor Contributes to the Prostate Cancer-Induced Osteoblast Differentiation Mediated by Bone Morphogenetic Protein

Dai, J., Kitagawa, Y., Zhang, J., Yao, Z., Mizokami, A., Cheng, S., Nor, J. E., McCauley, L. K., Taichman, R. S., & Keller, E. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1382 · Cited by 147

Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.

Fizazi, K. S., Yang, J., Peleg, S., Sikes, C. R., Kreimann, E. L., Daliani, D., Olivé, M., Raymond, K. A., Janus, T. J., Logothetis, C. J., et al. (2003) · PubMed · Cited by 147

Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells

Harris, S. E., Harris, M. A., Mahy, P., Feng, J. Q., Mundy, G. R., & Wozney, J. M. (1994) · The Prostate · doi:10.1002/pros.2990240406 · Cited by 144

Complete amino acid sequence of human transforming growth factor type beta 2.

Marquardt, H., Lioubin, M. N., & Ikeda, T. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45325-2 · Cited by 136

Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow.

Chackal-Roy, M., Niemeyer, C. M., Moore, M., & Zetter, B. R. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114167 · Cited by 133

Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.

Yang, J., Fizazi, K. S., Peleg, S., Sikes, C. R., Raymond, A. K., Jamal, N., Hu, M. C. ‐., Olivé, M., Martinez, L. A., Wood, C. G., et al. (2001) · PubMed · Cited by 131

The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae

Takuwa, Y., Masaki, Τ., & Yamashita, K. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)90491-5 · Cited by 129

Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies

Autzen, P., Robson, C. N., Bjartell, A. S., Malcolm, A. J., Johnson, M. I., Neal, D. E., & Hamdy, F. C. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.658 · Cited by 123

Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.

Brown, J. M., Vessella, R. L., Kostenuik, P. J., Dunstan, C. R., Lange, P. H., & Corey, E. (2001) · PubMed · Cited by 113

The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.

Han, S. H., de Klerk, J. M. H., Tan, S., Schip, A. D. V. H., Derksen, B. H., van Dijk, A., Kruitwagen, C. L. J. J., Blijham, G. H., van Rijk, P. P., & Zonnenberg, B. A. (2002) · PubMed · Cited by 90

Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.

Lee, Y.-P., Schwarz, E. M., Davies, M., Jo, M., Gates, J. J., Zhang, X., Wu, J., & Lieberman, J. R. (2002) · PubMed · Cited by 88

WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma.

Pinthus, J. H., Waks, T., Schindler, D. G., Harmelin, A., SAID, J. W., Belldegrun, A. S., Ramon, J., & Eshhar, Z. (2000) · PubMed · Cited by 61

Growth Regulatory Factors and Bone

Mundy, G. R., Chen, D., Zhao, M., Dallas, S. L., Xu, C., & Harris, S. (2001) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1010015309973 · Cited by 57

Establishment and characterization of a new human prostatic cancer cell line: DuCaP.

Lee, Y.-G., Korenchuk, S., Lehr, J. E., Whitney, S. C., Vessela, R., & Pienta, K. J. (2001) · PubMed · Cited by 52

A Neuroendocrine/Small Cell Prostate Carcinoma Xenograft—LuCaP 49

True, L. D., Buhler, K. R., Quinn, J. E., Williams, E., Nelson, P. S., Clegg, N. J., Macoska, J. A., Norwood, T. H., Liu, A. Y. C., Ellis, W., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64226-5 · Cited by 51

Stimulation of human prostate cancer cell lines by factors present in human osteoblast‐like cells but not in bone marrow

Lang, S., Miller, W. R., & Habib, F. K. (1995) · The Prostate · doi:10.1002/pros.2990270508 · Cited by 37

In Situ Expression of mRNA for Proto-Oncogenes in Benign Prostatic Hyperplasia and in Prostatic Carcinoma

Funa, K., Nordgren, H., & Nilsson, S. F. (1991) · Scandinavian Journal of Urology and Nephrology · doi:10.3109/00365599109024540 · Cited by 19

Concepts of extracellular matrix remodelling in tumour progression and metastasis

Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296

Pre-metastatic niches: organ-specific homes for metastases

Peinado, H., Zhang, H., Matei, I. R., Costa-Silva, B., Hoshino, A., Rodrigues, G., Psaila, B., Kaplan, R. N., Bromberg, J. F., Kang, Y., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.6 · Cited by 1,889

Metastatic tumours to the oral cavity – Pathogenesis and analysis of 673 cases

Hirshberg, A., Shnaiderman-Shapiro, A., Kaplan, I., & Berger, R. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2007.09.012 · Cited by 532

Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy

Jiao, S., Subudhi, S. K., Aparicio, A., Ge, Z., Guan, B., Miura, Y., & Sharma, P. (2019) · Cell · doi:10.1016/j.cell.2019.10.029 · Cited by 386

Study of matrix metalloproteinases and their inhibitors in breast cancer

Vizoso, F. J., González, L. O., Corte, M. D., Rodríguez, J. C., Vázquez, J., Lamelas, M. L., Junquera, S., Merino, A. M., & García-Muñiz, J. L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603666 · Cited by 271